Filemon Dela Cruz, MD

Memorial Sloan Kettering pediatric oncologist Filemon Dela Cruz
LocationA pin, used as a metaphor for the concept of location. Locations Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
Phone iconAn icon showing a telephone. New Patient Appointments Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
Phone iconAn icon showing a telephone. Phone Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

About Me

I am a pediatric oncologist who cares for children with sarcomas, including Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and desmoplastic small round cell tumors. I am also actively involved in the pediatric precision medicine program we are developing at Memorial Sloan Kettering. Through this program, we will harness genetic information about each patient’s tumor and use it to help guide treatment. Our goal is to not only cure more children, adolescents, and young adults, but also to improve quality of life for our patients by reducing short and long-term effects that can be caused by traditional treatments.  

Oncology is a rapidly evolving field. With new technologies, such as next-generation sequencing and patient-derived xenograft (PDX) models, we have been able to gather incredible insights into the biology and genetics of cancer. As a result, we are able to identify and test new targeted treatments that are specifically tailored to an individual’s cancer. This is called precision medicine.

I am working with groups at MSK and across the nation (through the Children’s Oncology Group) to develop and utilize PDX tumor models to learn more about the biology of various cancers. These models are genetic replicas of a patient’s tumor and allow us to test new treatments without having to involve the patient. I will also be the principal investigator of an upcoming phase I/II trial in pediatric sarcomas and high-grade glioma to study the combination of two drugs: lenvatinib and everolimus.

A cancer diagnosis and its treatment is an unimaginably difficult journey for children, adolescents, young adults, and their parents and caregivers. I am continually inspired by the relationships among these families as they face challenges together. It is my job to make sure they know that we are here to guide them through treatment, and that we will provide world-class care to ensure their child has the best possible outcome. 

  • Clinical Expertise: Pediatric Sarcomas; Ewing sarcoma; Osteosarcoma; Rhabdomyosarcoma; Desmoplastic Small Round Cell Tumor
  • Languages Spoken: English
  • Education: MD, University of California, Davis
  • Residencies: University of California, San Francisco
  • Fellowships: Columbia University Medical Center
  • Board Certifications: Pediatrics; Pediatric Hematology/Oncology

See My Colleagues


Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Tannenbaum-Dvir S, Glade Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Cold Spring Harbor molecular case studies. 2015; 1(1):a000471.

A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A, Andrews SJ, Mansukhani MM, Nagy PL, Alvarez MJ, Califano A, Forouhar F, Modzelewski B, Mitchell CM, Yamashiro DJ, Marks LJ, Bender JL, Kung AL. Genome medicine. 2016; 8(1):116.

Visit PubMed for a full listing of Filemon Dela Cruz’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicare and New York State Medicaid also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.